AbbVie inks $757m migraine-focused deal with Brise Pharmaceuticals
AbbVie and Brise have shared details on this migraine deal two years after it was originally forged.
AbbVie and Brise have shared details on this migraine deal two years after it was originally forged.
Anthropic hopes Powerful AI will “match or exceed the cognitive capabilities of top human experts across scientific disciplines”.
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms,...
Drug delivery’s next bottleneck isn’t innovation, it’s industrial capacity
Australia starts investigation into OpenAI Medicare breach
How DFE Pharma supports confident continuous manufacturing decisions
Industry partnership will determine the success of the transition to low-GWP pMDIs